Defining Bepirovirsen Candidates in Chronic Hepatitis B

The approval defines a limited population

The FDA’s 2026 novel drug approvals record lists bepirovirsen as a newly approved treatment for chronic hepatitis B. The central clinical point is one of eligibility: this is not a general indication for everyone with hepatitis B virus infection, and it does not displace standard oral antiviral treatment.

The approved population comprises certain adults with chronic hepatitis B who do not have cirrhosis. Bepirovirsen is used in combination with existing antiviral therapy, meaning the background nucleos(t)ide analog remains part of treatment. The FDA listing should therefore not be interpreted as support for switching a virologically suppressed patient from oral therapy to bepirovirsen alone.

That distinction matters because oral nucleos(t)ide analogs and bepirovirsen serve different purposes. Agents such as entecavir, tenofovir alafenamide and tenofovir disoproxil fumarate inhibit viral replication. Bepirovirsen is an antisense oligonucleotide designed to reduce hepatitis B viral RNA and, consequently, viral proteins including hepatitis B surface antigen. The therapeutic strategy is additive: maintain suppression while targeting viral antigen production through another mechanism.

The phrase “certain adults” also signals that age, cirrhosis status and concurrent treatment are not the only considerations. Clinicians should use the full FDA prescribing information to confirm all label-defined virologic, laboratory and treatment-history requirements. A summary listing of novel drugs cannot substitute for the indication, contraindications, warnings, monitoring provisions and instructions in the approved label.

What the clinical evidence showed

Earlier randomized evidence established that bepirovirsen could produce sustained loss of detectable hepatitis B surface antigen and viral DNA in a minority of selected participants. In the double-blind, phase 2b B-Clear trial, 457 adults with chronic hepatitis B were randomly assigned to one of four bepirovirsen or placebo schedules. Participants were enrolled in strata according to whether they were already receiving nucleos(t)ide analog therapy.

The primary outcome was hepatitis B surface antigen and HBV DNA below the assay limits of quantification, maintained for 24 weeks after the planned end of bepirovirsen treatment without newly initiated antiviral medication. Among participants receiving background nucleos(t)ide analog therapy, the outcome occurred in 6 of 57 participants, or 10%, in one 24-week bepirovirsen group and 6 of 56, or 11%, in a second active-treatment group. It occurred in 2 of 56 participants, or 4%, in a shorter-treatment group and in none of 56 assigned to placebo.

Results were similar in the stratum not receiving nucleos(t)ide analog therapy: 7 of 58 participants, or 12%, and 6 of 57, or 11%, met the primary outcome in the two longer active-treatment groups, compared with 1 of 59, or 2%, in the shorter-treatment group and none of 58 in the placebo group. The publication reported that responses were more frequent among participants with lower hepatitis B surface antigen levels at baseline.

These findings showed biological and clinical activity, but they should not be read as the complete basis for the eventual approved indication. B-Clear was a phase 2 dose- and schedule-ranging trial, and its nucleos(t)ide analog–free stratum does not override the FDA-approved combination-treatment framework. Trial regimens likewise should not be converted into prescribing instructions; dosing and monitoring must come from the final label.

Adverse events in B-Clear included injection-site reactions, fever and alanine aminotransferase elevations. An increase in aminotransferases can accompany immune activity against infected hepatocytes, but it may also signal clinically important liver injury. This makes baseline hepatic assessment and label-directed monitoring particularly relevant, especially in a disease whose severity can be underestimated by symptoms alone.

How to identify candidates in practice

The first step is to separate diagnosis from treatment eligibility. A positive hepatitis B surface antigen result alone does not establish that a patient meets every criterion for bepirovirsen. Chronicity, current antiviral therapy, virologic status, liver disease stage and the full label requirements all need review.

Cirrhosis assessment is a decisive boundary. A patient with known cirrhosis does not fall within the population described by the approval, even if viral replication is suppressed and other laboratory findings appear favorable. When cirrhosis status is uncertain, the approval does not justify assuming its absence. Clinical history, laboratory measures, imaging and validated noninvasive fibrosis assessment may all contribute to staging under routine hepatitis B care.

For eligible adults already taking a nucleos(t)ide analog, treatment reconciliation should make clear that the oral antiviral continues unless a separate label-supported clinical decision is made. Suppression of HBV DNA reduces the risk of virologic rebound and hepatic flares. Bepirovirsen should not be presented as permission to stop established therapy prematurely.

The approval also does not expand treatment to acute hepatitis B, hepatitis B exposure prophylaxis or pediatric infection. Nor should phase 2 findings be extrapolated to people with decompensated liver disease, transplant recipients or other groups who were not represented adequately in the supporting population. Chronic hepatitis B management still includes evaluation for coinfections, medication interactions, renal and hepatic status, and hepatocellular carcinoma surveillance when indicated.

For policymakers and health systems, candidate identification will require more than adding a drug to a formulary. Pathways need to distinguish noncirrhotic from cirrhotic disease, document background antiviral treatment and support the laboratory monitoring specified by the label. Coverage criteria should track the FDA indication rather than broader trial enrollment categories or mechanistic expectations.

Important evidence gaps

The phase 2 response was meaningful for a subset of participants but uncommon overall, and baseline characteristics appeared to influence the probability of response. It remains important to understand how well later trial results translate across hepatitis B genotypes, racial and ethnic groups, geographic settings, stages of fibrosis and different background antivirals.

Durability is another issue. A response maintained for 24 weeks after treatment is clinically informative, but chronic hepatitis B can reactivate over a much longer horizon. Continued follow-up is needed to establish how often surface antigen loss persists, whether antibodies to surface antigen develop, how often virologic relapse occurs and whether treatment ultimately reduces cirrhosis, hepatic decompensation or hepatocellular carcinoma.

The randomized B-Clear trial supports causal conclusions about differences between its assigned regimens and placebo within the studied population. It was not powered or followed long enough to establish effects on major liver outcomes. Its sponsor involvement and selected eligibility criteria also limit generalizability. The FDA novel-drug listing confirms the regulatory action but is not a replacement for the complete approval package and prescribing information.

Questions clinicians ask

Can bepirovirsen replace tenofovir or entecavir?

No. The approved approach uses bepirovirsen with existing antiviral therapy. Oral nucleos(t)ide analog treatment should not be stopped merely because bepirovirsen is started; any change should be supported by the prescribing information and the patient’s virologic and hepatic status.

Is every noncirrhotic adult with chronic hepatitis B eligible?

No. Absence of cirrhosis is necessary but does not by itself establish eligibility. Clinicians must also confirm chronic infection, adult status, background antiviral treatment and every additional virologic, laboratory or treatment-history requirement stated in the full FDA label.

What if cirrhosis status is uncertain?

Uncertain staging should be resolved rather than treated as noncirrhotic disease by default. The stated approval excludes cirrhosis, so clinical history, laboratory findings, imaging and appropriate noninvasive fibrosis assessment should inform whether a patient fits the labeled population.

Does surface antigen loss mean follow-up can stop?

No. The phase 2 endpoint required surface antigen and HBV DNA below quantification for 24 weeks after treatment, but that interval does not establish lifelong remission. Longer-term monitoring remains important for virologic relapse, hepatic inflammation and liver cancer risk according to the patient’s underlying disease profile.

References

Novel Drug Approvals for 2026 — US Food and Drug Administration, 2026

Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection — The New England Journal of Medicine, 2022

A Study of GSK3228836 in Participants With Chronic Hepatitis B (B-Clear) — ClinicalTrials.gov, 2020

Hepatitis B — World Health Organization, 2024